GlassScriptPhysician profile
Jennifer Pickwell
NPI 1265606107
$8,930.33
in general payments reported to CMS, 2019-2025
54 companies · $2,716 in 2025
The $2,716 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,178 · 2022: $1,262 · 2023: $1,369 · 2024: $2,406 · 2025: $2,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,211 · Long Term Medical Supply Or Device Loan: $1,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,210.77 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,957.30 | 2022-2025 | |
| Celgene Corporation | $620.64 | 2021-2025 | Reblozyl, Pomalyst, Pomalyst |
| Janssen Biotech, INC. | $540.14 | 2021-2025 | Erleada, Tecvayli, Darzalex |
| Pfizer INC. | $431.82 | 2021-2025 | |
| Abbvie INC. | $402.28 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $388.06 | 2021-2025 | Tagrisso, Enhertu, Imfinzi |
| Incyte Corporation | $351.04 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| E.R. Squibb & Sons, L.L.C. | $309.27 | 2021-2025 | Pomalyst, Opdivo, Krazati |
| Amgen INC. | $301.10 | 2021-2024 | Kyprolis |
| Merck Sharp & Dohme LLC | $280.98 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Genentech USA, INC. | $249.31 | 2021-2025 | Polivy, Tecentriq, Columvi |
| Daiichi Sankyo INC. | $234.45 | 2021-2024 | Enhertu, Injectafer |
| Genzyme Corporation | $230.29 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $181.31 | 2021-2025 | |
| Eisai INC. | $157.16 | 2021-2025 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $153.62 | 2021-2025 | Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $150.50 | 2023-2025 | Ninlaro, Alunbrig |
| Seagen INC. | $147.62 | 2021-2023 | Padcev |
| Glaxosmithkline, LLC. | $134.92 | 2022-2024 | Ojjaara, Zejula |
| Regeneron Healthcare Solutions, INC. | $133.95 | 2021-2025 | Libtayo, Lynozyfic |
| Aveo Pharmaceuticals, INC. | $129.78 | 2022-2025 | Fotivda |
| Jazz Pharmaceuticals INC. | $100.67 | 2022-2025 | |
| Mirati Therapeutics, INC. | $98.09 | 2023-2024 | Krazati |
| Emd Serono, INC. | $95.93 | 2025 | |
| Deciphera Pharmaceuticals INC. | $92.21 | 2021-2025 | Qinlock, Romvimza |
| Pharmacyclics LLC, An Abbvie Company | $86.55 | 2023 | Imbruvica, Epkinly |
| Springworks Therapeutics, INC. | $68.12 | 2024-2025 | Ogsiveo |
| Gilead Sciences, INC. | $67.86 | 2023-2025 | Trodelvy |
| Ipsen Biopharmaceuticals, INC | $65.87 | 2022-2025 | Onivyde |
| Lilly USA, LLC | $64.90 | 2022-2025 | Retevmo, Jaypirca, Verzenio |
| Alexion Pharmaceuticals, INC. | $58.75 | 2021-2024 | Ultomiris |
| Array Biopharma INC | $55.08 | 2024-2025 | Xalkori, Mektovi, Braftovi |
| Myovant Sciences INC. | $54.65 | 2021-2022 | |
| Stemline Therapeutics INC. | $47.12 | 2021-2023 | Elzonris |
| G1 Therapeutics, INC. | $45.06 | 2022 | |
| Servier Pharmaceuticals LLC | $38.40 | 2022-2023 | |
| Puma Biotechnology, INC. | $38.29 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $34.72 | 2021-2022 | |
| Pharmaessentia USA Corporation | $33.78 | 2024 | Besremi |
| Karyopharm Therapeutics INC. | $30.13 | 2024 | Xpovio |
| Beigene USA, INC. | $28.98 | 2021-2022 | |
| Morphosys, US INC. | $26.83 | 2022-2023 | Monjuvi |
| Syndax Pharmaceuticals, INC. | $26.37 | 2025 | |
| Genmab U.S., INC. | $23.88 | 2025 | Epkinly |
| Pharmacosmos Therapeutics INC. | $23.78 | 2025 | Monoferric |
| Novocure INC. | $19.08 | 2025 | Optune Lua (Novottf-200t) |
| Beone Medicines USA, INC. | $17.67 | 2025 | Brukinsa |
| Acceleron Pharma, INC. | $17.31 | 2021 | |
| Clovis Oncology, INC. | $16.47 | 2021 | |
| Epizyme, INC. | $15.95 | 2021 | |
| Exelixis INC. | $15.92 | 2024 | Cabometyx |
| Dova Pharmaceuticals | $13.13 | 2021 | |
| Tersera Therapeutics LLC | $12.95 | 2022 | |
| Secura Bio, INC. | $10.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Pickwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.